FDAsafety guidance83% confidence
Guidance Documents for Rare Disease Drug Development
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to IMVT-1402.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Endocrinology · Graves' Disease
- Sub-indication
- General
Related signal: Immunovant's IMVT-1402 Enters Phase 2b for Graves' Disease Treatment